Tuesday, July 23, 2019 2:30:01 PM
About:
Curis , Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
SHORT INTEREST
453.34K 06/28/19
P/E Ratio (with extraordinary items)
-2.40
Further Information:
Each of the Q3 2019 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on July 1, 2019. Each stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates. Each stock option was granted as an inducement equity award outside of the Company's Third Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent CRIS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 12:08:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:05:25 PM
- Curis Provides Second Quarter 2024 Financial and Operating Update • PR Newswire (US) • 08/01/2024 12:00:00 PM
- Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- Curis to Present at Upcoming Healthcare Conference in July • PR Newswire (US) • 07/10/2024 11:30:00 AM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/08/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/14/2024 08:03:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:12:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:11:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:09:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:08:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:08:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:07:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:04:35 PM
- Curis Announces Additional Data from TakeAim Leukemia Study • PR Newswire (US) • 05/14/2024 08:00:00 PM
- Curis to Present Updated Data from the TakeAim Leukemia Study • PR Newswire (US) • 05/10/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:30:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:02:29 PM
- Curis Provides First Quarter 2024 Business Update • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:00:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 11:30:00 AM
- Curis to Present at Upcoming Healthcare Conferences in April • PR Newswire (US) • 04/04/2024 11:30:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM